Literature DB >> 20067773

A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.

Xiaolei Zhang1, Peibin Yue, Steven Fletcher, Wei Zhao, Patrick T Gunning, James Turkson.   

Abstract

The molecular modeling of the phosphotyrosine (pTyr)-SH2 domain interaction in the Stat3:Stat3 dimerization, combined with in silico structural analysis of the Stat3 dimerization disruptor, S3I-201, has furnished a diverse set of analogs. We present evidence from in vitro biochemical and biophysical studies that the structural analog, S3I-201.1066 directly interacts with Stat3 or the SH2 domain, with an affinity (K(D)) of 2.74microM, and disrupts the binding of Stat3 to the cognate pTyr-peptide, GpYLPQTV-NH(2), with an IC(50) of 23microM. Moreover, S3I-201.1066 selectively blocks the association of Stat3 with the epidermal growth factor receptor (EGFR), and inhibits Stat3 tyrosine phosphorylation and nuclear translocation in EGF-stimulated mouse fibroblasts. In cancer cells that harbor aberrant Stat3 activity, S3I-201.1066 inhibits constitutive Stat3 DNA-binding and transcriptional activities. By contrast, S3I-201.1066 has no effect on Src activation or the EGFR-mediated activation of the Erk1/2(MAPK) pathway. S3I-201.1066 selectively suppresses the viability, survival, and malignant transformation of the human breast and pancreatic cancer lines and the v-Src-transformed mouse fibroblasts harboring persistently active Stat3. Treatment with S3I-201.1066 of malignant cells harboring aberrantly active Stat3 down-regulated the expression of c-Myc, Bcl-xL, Survivin, the matrix metalloproteinase 9, and VEGF. The in vivo administration of S3I-201.1066-induced significant antitumor response in mouse models of human breast cancer, which correlates with the inhibition of constitutively active Stat3 and the suppression of known Stat3-regulated genes. Our studies identify a novel small-molecule that binds with a high affinity to Stat3, blocks Stat3 activation and function, and thereby induces antitumor response in human breast tumor xenografts harboring persistently active Stat3. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20067773      PMCID: PMC3188443          DOI: 10.1016/j.bcp.2010.01.001

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  54 in total

1.  Identification of a high-affinity phosphopeptide inhibitor of Stat3.

Authors:  Zhiyong Ren; Larry A Cabell; Timothy S Schaefer; John S McMurray
Journal:  Bioorg Med Chem Lett       Date:  2003-02-24       Impact factor: 2.823

Review 2.  Transcription factors as targets for cancer therapy.

Authors:  James E Darnell
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

Review 3.  The STATs of cancer--new molecular targets come of age.

Authors:  Hua Yu; Richard Jove
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

4.  Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells.

Authors:  Pedro J Real; Angels Sierra; Ana De Juan; Jose C Segovia; Jose M Lopez-Vega; Jose L Fernandez-Luna
Journal:  Oncogene       Date:  2002-10-31       Impact factor: 9.867

5.  Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer.

Authors:  M Wagner; J Kleeff; H Friess; M W Büchler; M Korc
Journal:  Pancreas       Date:  1999-11       Impact factor: 3.327

6.  Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells.

Authors:  Linda B Mora; Ralf Buettner; John Seigne; Jose Diaz; Nazeel Ahmad; Roy Garcia; Tammy Bowman; Robert Falcone; Rita Fairclough; Alan Cantor; Carlos Muro-Cacho; Sandy Livingston; James Karras; Julio Pow-Sang; Richard Jove
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

Review 7.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

Authors:  Ralf Buettner; Linda B Mora; Richard Jove
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

8.  Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.

Authors:  Michelle A Blaskovich; Jiazhi Sun; Alan Cantor; James Turkson; Richard Jove; Saïd M Sebti
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

9.  Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.

Authors:  Daoyan Wei; Xiangdong Le; Leizhen Zheng; Liwei Wang; Jennifer A Frey; Allen C Gao; Zhihai Peng; Suyun Huang; Henry Q Xiong; James L Abbruzzese; Keping Xie
Journal:  Oncogene       Date:  2003-01-23       Impact factor: 9.867

10.  Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity.

Authors:  James Turkson; Joon S Kim; Shumin Zhang; Jing Yuan; Mei Huang; Matthew Glenn; Eric Haura; Said Sebti; Andrew D Hamilton; Richard Jove
Journal:  Mol Cancer Ther       Date:  2004-03       Impact factor: 6.261

View more
  74 in total

1.  An activatable multimodal/multifunctional nanoprobe for direct imaging of intracellular drug delivery.

Authors:  Rajendra N Mitra; Mona Doshi; Xiaolei Zhang; Jessica C Tyus; Niclas Bengtsson; Steven Fletcher; Brent D G Page; James Turkson; Andre J Gesquiere; Patrick T Gunning; Glenn A Walter; Swadeshmukul Santra
Journal:  Biomaterials       Date:  2011-11-10       Impact factor: 12.479

Review 2.  Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.

Authors:  Chia Chi Sun; Valentina Vaja; Jodie L Babitt; Herbert Y Lin
Journal:  Am J Hematol       Date:  2012-01-31       Impact factor: 10.047

Review 3.  Therapeutic modulators of STAT signalling for human diseases.

Authors:  Gabriella Miklossy; Tyvette S Hilliard; James Turkson
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

4.  A potent and selective inhibitor for the UBLCP1 proteasome phosphatase.

Authors:  Yantao He; Xing Guo; Zhi-Hong Yu; Li Wu; Andrea M Gunawan; Yan Zhang; Jack E Dixon; Zhong-Yin Zhang
Journal:  Bioorg Med Chem       Date:  2015-03-31       Impact factor: 3.641

5.  Total Saponins of Rubus Parvifolius L. Exhibited Anti-Leukemia Effect in vivo through STAT3 and eIF4E Signaling Pathways.

Authors:  Xiao-Feng Xu; Ru-Bin Cheng; Xue-Jin Zhang; Rui-Lan Gao
Journal:  Chin J Integr Med       Date:  2018-05-11       Impact factor: 1.978

6.  A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation.

Authors:  Xiaolei Zhang; Ying Sun; Roberta Pireddu; Hua Yang; Murali K Urlam; Harshani R Lawrence; Wayne C Guida; Nicholas J Lawrence; Saïd M Sebti
Journal:  Cancer Res       Date:  2013-01-15       Impact factor: 12.701

7.  XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.

Authors:  Yan Cheng; Michael P Holloway; Kevin Nguyen; Dilara McCauley; Yosef Landesman; Michael G Kauffman; Sharon Shacham; Rachel A Altura
Journal:  Mol Cancer Ther       Date:  2014-01-15       Impact factor: 6.261

Review 8.  Targeting SH2 domains in breast cancer.

Authors:  Pietro Morlacchi; Fredika M Robertson; Jim Klostergaard; John S McMurray
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

9.  Linker Variation and Structure-Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors.

Authors:  Francisco Lopez-Tapia; Christine Brotherton-Pleiss; Peibin Yue; Heide Murakami; Ana Carolina Costa Araujo; Bruna Reis Dos Santos; Erin Ichinotsubo; Anna Rabkin; Raj Shah; Megan Lantz; Suzie Chen; Marcus A Tius; James Turkson
Journal:  ACS Med Chem Lett       Date:  2018-02-16       Impact factor: 4.345

10.  Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations.

Authors:  Shengjuan Shao; Rilei Yu; Yanqing Yu; Yanni Li
Journal:  J Mol Model       Date:  2014-08-07       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.